Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1666073

registered interest
date	19/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of (a) the potential impact of the level of the Voluntary Scheme for Branded Medicines Pricing and Access payment percentages on and (b) other factors affecting the decisions by pharmaceutical companies on whether to invest in the UK.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	203482
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>The Government has considered in broad terms the link between volume-based rebate payments in our medicine pricing schemes and various kinds of investment in our Impact Assessment of updates to the Statutory Scheme for branded medicines pricing, which operates alongside voluntary scheme for branded medicines pricing and access. The Government’s 2023 Impact Assessment of updates to the Statutory Scheme is available at the following link:</p><p><a href="https://www.gov.uk/government/consultations/review-of-the-scheme-to-control-the-cost-of-branded-health-service-medicines" target="_blank">https://www.gov.uk/government/consultations/review-of-the-scheme-to-control-the-cost-of-branded-health-service-medicines</a></p><p>We are in close discussions with the Department for Science, Innovation and Technology and the Department for Business and Trade about the business environment for life sciences and its impact on investment.</p> answering member constituency Colchester answering member printed Will Quince question first answered 24/10/2023 14:53:13 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1662056

registered interest
date	19/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of introducing regular reporting to Parliament on (a) the progress and (b) the impact on private sector research and development of the Voluntary Scheme for Branded Medicines Pricing and Access.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	200305
answer	answer is ministerial correction date of answer 17/10/2023 answer text <p>The Department has no plans to re-instate the reports to Parliament on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which were a requirement under the 2014 The Pharmaceutical Price Regulation Scheme (PPRS). This requirement was removed from the 2019 VPAS with the agreement of the Association of the British Pharmaceutical Industry.</p><p>We are open to ideas about how a successor voluntary scheme should operate from 2024 onwards and look forward to working with industry to agree a mutually beneficial scheme that supports the sustainability of National Health Service spend on branded medicines, better patient outcomes and enables a strong life sciences industry in the United Kingdom.</p> answering member constituency Colchester answering member printed Will Quince question first answered 17/10/2023 09:30:43 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1661311

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Newcastle upon Tyne
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support NHS patients in Newcastle who are withdrawing from prescription anti-depressants.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	199960
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>In March 2023, NHS England published “Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: framework for action”. Developed in partnership with integrated care system leads this framework sets out actions to help systems develop plans that can support people who are taking medicines associated with dependence and withdrawal symptoms. The actions are supporting ICSs to deliver on their 4 key objectives of:</p><p>- improving outcomes in population health and healthcare;</p><p>- tackling health inequalities in outcomes, experience and access;</p><p>- enhancing productivity and value for money; and</p><p>- helping the NHS support broader social and economic development.</p><p> </p><p>The actions have been co-produced with a range of stakeholders including:</p><p>- patients with lived experience and groups representing them;</p><p>- charities and voluntary sector organisations;</p><p>- clinical experts; and</p><p>- national organisations, for example the National Institute for Health and Care Excellence.</p><p>Under the guidance of the prescribing professional, someone who is stopping antidepressants may be advised to start or continue psychological or psychosocial interventions. Examples of such services in Newcastle include Talking Therapies (formerly known as Improving Access to Psychological Therapies), mental health support in the voluntary and community sector, online confidential advice and support, and social prescribing.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 09:59:34 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1657764

registered interest
date	04/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovation and Life Sciences: North East
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what (a) life sciences and (b) health innovation programmes his Department provides funding to in the North East.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	197405
answer	answer is ministerial correction date of answer 12/09/2023 answer text <p>The Department supports the United Kingdom life sciences sector via the Office for Life Sciences and provides funding for research infrastructure across the whole of England through the National Institute for Health and Care Research (NIHR).</p><p>In the North East, the Newcastle Health Innovation Partners (NHIP) works with innovators to discover, develop and deliver new solutions in healthcare to improve the health of its population. The NHIP brings together the NIHR research infrastructure, the NIHR Clinical Research Network and the Academic Health Science Network for the North East and North Cumbria.</p><p>The Government’s Life Sciences Innovative Manufacturing Fund supports businesses investing in life sciences manufacturing projects in the UK. Two companies in the North East have been awarded funding.</p> answering member constituency Colchester answering member printed Will Quince question first answered 12/09/2023 13:04:22 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1657765

registered interest
date	04/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials: North East
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to increase clinical trials capacity in the North East.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	197406
answer	answer is ministerial correction date of answer 06/09/2023 answer text <p>To increase clinical trials capacity in the North East, the Department provides funding through the National Institute for Health and Care Research (NIHR) infrastructure in line with the Government’s Vision for the Future of UK Clinical Research. This includes investment in the NIHR Clinical Research Network (CRN), NIHR Clinical Research Facility (CRF) and NIHR Patient Recruitment Centre (PRC).</p><p>The NIHR CRN supports patients, the public and health and care organisations throughout England to participate in high-quality research; the NIHR Local CRN North East and North Cumbria facilitates effective and efficient clinical trial participation, setup and delivery across the North East. Newcastle upon Tyne Hospitals NHS Foundation Trust was recently re-awarded funding for the NIHR Newcastle CRF for delivery of high-quality experimental medical research and early phase clinical trials. Newcastle upon Tyne Hospitals NHS Foundation Trust also hosts one of five NIHR PRCs, a facility dedicated to delivering commercial research. In addition, NIHR recently awarded capital funding for new research equipment to NHS trusts, of which the North East received over £4 million.</p> answering member constituency Colchester answering member printed Will Quince question first answered 06/09/2023 15:23:01 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652435

registered interest
date	12/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Waiting Lists
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of which NHS Trusts (a) were and (b) were not on track to meet their 18 month targets in the elective recovery plan as of 1 July 2023.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193650
answer	answer is ministerial correction date of answer 18/07/2023 answer text <p>Thanks to the work of National Health Service staff, we have now virtually eliminated waits of over 18 months, in line with the targets set out in the elective recovery plan.</p><p>The most recently published NHS England management information showed that on 2 July there were 7,363 patients waiting over 18 months, a reduction of over 94% from the peak of 125,000 in September 2021.</p><p> </p><p>As of 2 July, 31 trusts have no patients waiting 18 months or more, whilst 114 of the 136 trusts have less than 100 remaining.</p> answering member constituency Colchester answering member printed Will Quince question first answered 18/07/2023 11:43:38 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652436

registered interest
date	12/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Arthritis: Mental Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has made an assessment of the potential impact of waiting times for elective care on the mental health of people with arthritis.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193651
answer	answer is ministerial correction date of answer 19/07/2023 answer text <p>The Department has not made any assessment of this potential impact. However, cutting waiting lists is one of the Government’s top priorities. We are making good progress on tackling the longest waits, to ensure patients get the care they need when they need it.</p><p>To support elective recovery, the Government plans to spend more than £8 billion from 2022/23 to 2024/25, in addition to the £2 billion Elective Recovery Fund, to help drive up and protect elective activity. As part of the Autumn Statement 2022, the Government announced an additional £3.3 billion for 2023/24 and 2024/25 to support the National Health Service in England, enabling rapid action to improve emergency, elective and primary care performance towards pre-pandemic levels. Taken together, this funding could deliver the equivalent of around nine million more checks and procedures and will mean that the NHS in England can aim to deliver around 30% more elective activity by 2024/25 than before the pandemic.</p><p>We met our target to virtually eliminate long waits of two years or more for elective procedures in July 2022, and significantly reduced the number of patients waiting 18 months or more by April 2023 by over 91% from its peak in September 2021.</p><p>Our next ambition is to eliminate waits of 65 and 52 weeks. Steps being taken include increasing capacity, seeking alternate capacity in other trusts or the independent sector, and engaging with patients to understand their choices.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/07/2023 16:22:29 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652047

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Arthritis and Musculoskeletal Disorders: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has taken recent steps to help increase (a) public and (b) private research into treatments for (i) arthritis and (ii) musculoskeletal conditions.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193374
answer	answer is ministerial correction date of answer 13/07/2023 answer text <p>The Department, through the National Institute for Health and Care Research (NIHR), has awarded more than £100 million in funding and support for musculoskeletal conditions and arthritis research in the last five years.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including research into musculoskeletal conditions and arthritis. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. Therefore, future spend on arthritis and musculoskeletal research is undetermined.</p><p>In 2021/22 alone, NIHR infrastructure has supported over 900 studies and trials into musculoskeletal conditions. Six of the NIHR Biomedical Research Centres (BRCs) have musculoskeletal disorders as a research theme. For example, the Leeds BRC aims to improve treatment for osteoarthritis and to prevent disease and disability in immune-mediated diseases; this includes a work stream on non-surgical treatments for osteoarthritis. NIHR, in collaboration with Versus Arthritis, also funds a dedicated UK Musculoskeletal Translational Research Collaboration (UK MSK TRC). The UK MSK TRC aligns investment in musculoskeletal translational research, creating a United Kingdom-wide ambition and focus to drive cutting-edge translational research, in order to improve outcomes for patients.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/07/2023 16:30:34 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652049

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made in implementing the recommendations of the Commercial clinical trials in the UK: the Lord O’Shaughnessy review, published 25 May 2023.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193376
answer	answer is ministerial correction date of answer 14/07/2023 answer text <p>On 26 May the Government published its initial response to the Lord O’Shaughnessy review into commercial clinical trials in the United Kingdom. This welcomed all recommendations in principle and made five headline commitments. A fuller response on all the recommendations and an implementation update and longer-term plan will be published in the autumn.</p> answering member constituency Colchester answering member printed Will Quince question first answered 14/07/2023 13:45:05 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652119

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Plantir: Newcastle upon Tyne Hospitals NHS Foundation Trust
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason the Palantir Foundry pilot at Newcastle Hospitals NHS Foundation Trust has been paused; and whether there are (a) financial and (b) operational costs as a result of the pilot's pausing.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193403
answer	answer is ministerial correction date of answer 20/07/2023 answer text <p>The implementation of Foundry products in Newcastle Hospitals NHS Foundation Trust is centred around two key solutions using the platform.</p><p>The first of these is the Improving Elective Care Coordination for Patients Programme (IECCP), which provides solutions designed to: validate waiting lists to ensure accuracy; enable clinicians to tell patients where they are on the waiting list and easily reprioritise them where required; and calculate the number of un-booked minutes in a theatre session and ‘suggest’ patients to fill gaps based on their priority, making theatre scheduling significantly more efficient. The rollout of IECCP at Newcastle Hospitals NHS Foundation Trust has been live since March 2023.</p><p>The second of these is the OPTICA solution deployed as part of the Dynamic Discharges programme of work, which is designed to: provide a blueprint to help the National Health Service manage the way patients are discharged, freeing up beds for those in most need; increase the timeliness of discharge for patients; and improve bed utilisation. Rollout of the OPTICA solution at Newcastle Hospitals NHS Foundation Trust is dependent on the implementation of the IECCP modules (which were completed in March 2023) and updates to the Trust’s Electronic Patient Record to enable electronic collection of discharge information.</p><p>Due to operational pressures, the Trust temporarily paused engagement of OPTICA. However, it is now in a position to recommence activity.</p><p> </p><p> </p><p>No costs have been incurred as a result of the pause in delivery because the OPTICA implementation resources originally allocated to the Trust were diverted to implement the solution in other trusts. However, the OPTICA Team is now scheduled to begin discussions with the Newcastle Hospitals NHS Foundation Trust to implement OPTICA as quickly as the Trust can accommodate.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/07/2023 16:11:05 answering member 4423 label Biography information for Will Quince previous answer version 88181 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah